Perrigo Company plc Payments to Acquire Marketable Securities
Perrigo Company plc (PRGO) reported Payments to Acquire Marketable Securities of $7.50 million for the 9-month period ending 2018-09-29, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2018-11-08
- Perrigo Company plc payments to acquire marketable securities for the quarter ending 2018-09-29 was $0.00.
- Perrigo Company plc payments to acquire marketable securities for the quarter ending 2017-09-30 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month |
|---|---|---|---|
| 2018-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $7.50M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $7.50M 10-Q · filed 2018-08-09 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | |
| 2017-07-01 | $0.00 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |